The sampling port is joined to the side of its existing neonatal flow sensor.
This enables clinicals to follow the correct protocols of using both lung protective protective volume control and CO2 monitoring, giving the baby the best chance of survival and limiting the possibility of longer-term conditions, such as cerebral palsy or lung disease.
It achieves this by combining the sensor for measuring flow volume with the optimally placed sampling port for safely extracting gas for tidal flow CO2 monitoring, reducing the ‘dead space’ found in existing products and ensuring more accurate readings.
Europlaz claims that the medical innovation can help improve neonatal care and save the lives of premature or distressed babies. The company also thinks the technology can reduce costs in the NHS and avoid expensive litigations.
“We are dealing with the tiniest of lives, so it is imperative that we give clinical teams the best possible technology to help them do their jobs. This is exactly what this innovation does, with the side sampling port delivering the stable and accurate readings of CO2 being exhaled that they need to better inform the care of the child, and the level of ventilation support required.”
He continued: “Europlaz has been manufacturing neonatal flow sensors for more than ten years and we have sold over 1million to date – all without the sampling port. This must change, and we believe that when one hospital or manufacturer commits to it, the rest will follow.
“It just makes too much sense not to. Why not embrace a product that gives you greater clarity, greater control and a greater chance of saving a baby’s life?
“There is also a financial element to it as well, with 60% of the NHS’ Resolution’s £9bn liability budget spent in 2018/19 dealing with cases involving maternity care.”
Continuing with its support in neonatal developments, Europlaz plans to introduce its new robotic welder shortly. This is the central element to a modern production cell that uses vision controlled micro-robotic wire welding to deliver highly consistent sensor quality, performance and reliability.
The company also a few weeks away from starting exciting trials of its own range of neonatal ventilation monitors at four major UK hospitals.
